Onco-hematology
Practice review: Evidence-based and effective management of fatigue in patients with advanced cancer.
1 Apr, 2022 | 08:26h | UTC
Review: The use of virtual care in patients with hematologic malignancies.
1 Apr, 2022 | 08:18h | UTC
Guidance on the need for contraception related to use of pharmaceuticals: providing information on the proper use of pharmaceuticals in patients with reproductive potential.
31 Mar, 2022 | 07:49h | UTC
Review | Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
28 Mar, 2022 | 08:47h | UTCPreparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
In a new Review now online, @abouelem and co-authors discuss the preparation and management of patients with cancer before #CARTcells, an area in which evidence on optimal conditions needs to grow https://t.co/Sb6rgcOTTJ pic.twitter.com/wjRrPDpoT7
— NatureRevClinOncol (@NatRevClinOncol) March 23, 2022
Cohort study: Long-term treatment with clozapine is associated with increased risk of hematological malignancies.
28 Mar, 2022 | 08:43h | UTCLong-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
Clozapine associated with an increased risk of haematological malignancies with a dose-response effect.
More deaths than from agranulocytosis, but absolute risk small compared to overall mortality benefit with clozapine.https://t.co/BK3P7GgPiv
@TheLancetPsych— Jonathan Rogers (@drjprogers) March 24, 2022
First case of HIV cure in a woman after stem cell transplantation reported at CROI-2022.
28 Mar, 2022 | 08:46h | UTC
Phase 2 RCT: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia.
21 Mar, 2022 | 08:22h | UTCVenetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW: Results from the HOVON 139/GiVe, ph 2 trial show that consolidation with venetoclax after fixed-duration venetoclax + obinutuzumab in patients w/ previously untreated CLL increases known side-effects & does not prevent MRD and risk of relapse #lymsm https://t.co/VzCUSHPMrp pic.twitter.com/PB62XNLAIK
— The Lancet Haematology (@TheLancetHaem) March 2, 2022
RCT: Efficacy of Plinabulin vs. Pegfilgrastim for prevention of docetaxel-induced neutropenia in patients with solid tumors.
18 Mar, 2022 | 08:00h | UTC
Commentary on Twitter
This RCT found that same-day plinabulin, a novel selective immunomodulating microtubule binding agent (SIMBA), is noninferior to next-day pegfilgrastim in chemotherapy-induced neutropenia prevention in patients receiving docetaxel chemotherapy. https://t.co/tUXuffISmB pic.twitter.com/LROsd3trPv
— JAMA Network Open (@JAMANetworkOpen) January 27, 2022
RCT: Bortezomib in newly diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
18 Mar, 2022 | 07:50h | UTCChildren’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
17 Mar, 2022 | 08:45h | UTC
NCCN Guideline: T-Cell Lymphomas.
15 Mar, 2022 | 08:41h | UTC
Safety and efficacy of antibiotic de-escalation and discontinuation in high-risk hematological patients with febrile neutropenia: a single-center experience.
10 Mar, 2022 | 10:09h | UTCRelated: Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology
Commentary on Twitter
OFID: In high-risk hematological patients w/ febrile neutropenia, antibiotic de-escalation and discontinuation prior to neutrophil recovery did not lead to an increase in infectious complications. https://t.co/eUer1fmoc6 #IDSAJournals @PaulSaxMD @DrJLi @FungalDoc @jobadd pic.twitter.com/HuGRYA8YW3
— IDSA (@IDSAInfo) January 5, 2022
Review: Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
9 Mar, 2022 | 08:35h | UTC
M-A: Efficacy of covid-19 vaccines in immunocompromised patients.
4 Mar, 2022 | 10:01h | UTCNews Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom
Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Commentary on Twitter
NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav
— The BMJ (@bmj_latest) March 3, 2022
Guideline: Management of Clostridioides difficile infection in hematopoietic cell transplant recipients.
3 Mar, 2022 | 08:17h | UTCSee other articles in the series:
SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients.
2 Mar, 2022 | 08:51h | UTC
Review: Cancer-associated venous thromboembolism.
21 Feb, 2022 | 08:42h | UTCCancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Related:
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
Isatuximab plus pomalidomide and low-dose dexamethasone vs. pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
21 Feb, 2022 | 08:13h | UTCIsatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
16 Feb, 2022 | 10:13h | UTC
Commentary on Twitter
A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig
— Eric Topol (@EricTopol) February 15, 2022
Australasian Consensus Guidelines for the use of antifungal agents in the hematology-oncology setting.
9 Feb, 2022 | 08:49h | UTCConsensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
Expert Consensus: Treatment algorithm in cancer-associated thrombosis.
9 Feb, 2022 | 08:42h | UTC
Review: Diagnosis and Management of Multiple Myeloma.
2 Feb, 2022 | 08:11h | UTCDiagnosis and Management of Multiple Myeloma: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis and Management of Multiple Myeloma – JAMA
RCT: Olanzapine may improve the control of vomiting in the delayed phase in children receiving highly emetogenic chemotherapy.
30 Jan, 2022 | 14:13h | UTCEfficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial – Journal of Pediatric Hematology/Oncology (link to abstract – $ for full-text)
Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
30 Jan, 2022 | 14:11h | UTCOriginal Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
Related:
Clinical practice guideline on immune checkpoint inhibitor-related adverse events.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)
RCT: Axicabtagene Ciloleucel as second-line therapy for Large B-Cell Lymphoma.
30 Jan, 2022 | 13:41h | UTC
Commentary on Twitter
In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy. #ASH21 https://t.co/V1WfVJ2k9V pic.twitter.com/ZHUhx8es27
— NEJM (@NEJM) December 11, 2021